Voyager Technologies announced a new contract with Space LiinTech to manifest a new payload to the International Space Station, advancing microgravity-enabled drug discovery.
“The most important breakthroughs in space-enabled medicine will come from consistent, high-fidelity access to orbit,” said Matt Magaña, president, Space, Defense & National Security at Voyager. “Microgravity changes crystallization, growth dynamics and material properties at a fundamental level. Voyager enables access to space to harness those differences – not once, but continuously through the ISS and future space platforms.”
Under the contract, Voyager will provide mission integration, payload configuration support and end-to-end guidance to ensure safe operations aboard the ISS.
Space LiinTech’s new mission expands the company’s ongoing work in protein crystallization, a foundational technique for developing more effective therapeutics. The payload will evaluate how microgravity influences the formation, morphology, and quality of protein crystals – critical data that can lead to improved drug formulations on Earth. The mission will test an AI-driven automation and monitoring system for improved crystal formulations in space and verify the functional stability and reliability of the company’s new research module from launch to return.
“Our goal is to build the next frontier of pharmaceutical innovation,” said Byungho Kim, senior vice president, Space LiinTech. “This new mission with Voyager reflects the start of a strong, long-term partnership, and we plan to expand continuous space-based medicine research together over time. Working with Voyager allows us to operate confidently on the ISS while advancing a platform that will ultimately support broader in-space production of high-value medical technologies.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!